Akari Therapeutics

NASDAQ: AKTX · Real-Time Price · USD
1.00
0.03 (3.08%)
At close: Aug 15, 2025, 3:58 PM
1.00
0.00%
After-hours: Aug 15, 2025, 04:10 PM EDT

Akari Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a 13K 13K 13K 13K 1K 1K 1K 1.94K 1.95K 2.96K 3.99K 4.1K 4.13K 4.12K 4.04K 6.03K
Gross Profit
n/a -13K -13K -13K -13K -1K -1K -1K -1.94K -1.95K -2.96K -3.99K -4.1K -3.09K -3.08K -3K -5K
Operating Income
-19.18M -21.64M -20.16M -21.03M -22.79M -21.4M -23.61M -25.83M -22.44M -23.09M -22.95M -18.4M -16.91M -17.21M -18.24M -17.02M -18.6M
Interest Income
6K 8K 7.01K 4.01K 61.07K 89.07K 89.08K 89.1K 33.99K 8.35K 12.31K 13.67K 11.23K 10.6K 11.94K 16.7K 16.34K
Pretax Income
-17.93M -19.79M -19.52M -20.13M -15.58M -9.01M -8.95M -8.89M -11.57M -17.75M -20.09M -18.1M -16.76M -17.42M -18.46M -15.57M -19.54M
Net Income
-17.93M -19.79M -19.52M -20.13M -15.58M -9.01M -8.95M -8.89M -11.43M -17.54M -19.71M -17.69M -16.52M -17.25M -18.46M -15.59M -19.54M
Selling & General & Admin
9.71M 10.7M 10.35M 11.34M 15.05M 14.22M 15.24M 16.27M 13.29M 13.53M 11.82M 9.98M 9.17M 8.08M 8.29M 8.24M 8.98M
Research & Development
5.52M 6.98M 10.17M 14.47M 14.41M 13.86M 12.87M 11.87M 11.47M 11.88M 12.29M 8.41M 7.74M 9.13M 9.94M 8.78M 9.62M
Other Expenses
2.06M 2.06M 1.07M -2 -22.82K -22.82K -22.82K -22.82K -9.22K -16.31K -27.43K -30.99K -26.88K -19.77K -20.94K -17.38K -14.03K
Operating Expenses
17.29M 19.74M 17.97M 18.56M 22.21M 20.83M 20.78M 20.73M 17.34M 17.99M 20.4M 18.4M 16.91M 17.21M 18.24M 17.02M 18.6M
Interest Expense
299K 244K 120K 51K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a 3.69M 3.69M 3.69M 3.69M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
19.18M 21.64M 19.88M 20.47M 22.23M 20.83M 20.78M 20.73M 17.34M 17.99M 20.4M 18.4M 16.91M 17.21M 18.24M 17.02M 18.6M
Income Tax Expense
n/a n/a n/a n/a -0.00 -0.00 -0.00 -0.00 -136.17K -203.76K -378.95K -405.22K -239.96K -172.37K 2.82K -1.67M 708.79K
Shares Outstanding (Basic)
272.00 11.94K 12.19K 9.42K 6.73K 5.39K 5.06K 5.06K 3.74K 3.42K 3.42K 2.97K 2.68K 2.41K 2.32K 1.92K 1.92K
Shares Outstanding (Diluted)
272.00 11.94K 12.19K 9.42K 6.73K 5.39K 5.06K 5.06K 3.79K 3.42K 3.42K 2.97K 2.68K 2.41K 2.32K 1.92K 1.92K
EPS (Basic)
-13.72K -220 -240 -280 -260 -160 -200 -240 -360 -580 -720 -680 -720 -820 -1.1K -960 -1.3K
EPS (Diluted)
-13.72K -220 -240 -280 -260 -160 -200 -240 -360 -580 -720 -680 -720 -820 -1.1K -960 -1.3K
EBITDA
-17.73M -20.06M -20.21M -21.08M -17.57M -16.19M -18.4M -20.62M -22.43M -23.08M -22.94M -18.39M -16.91M -17.21M -18.23M -17.02M -18.6M
EBIT
-17.63M -19.97M -20.12M -21.09M -17.59M -16.19M -18.41M -20.62M -22.44M -23.09M -22.95M -18.4M -16.91M -17.21M -18.24M -17.02M -18.6M
Depreciation & Amortization
-57K -44K -43.93K -42.85K 17K 5K 4.95K 4.9K 3.99K 4K 3.98K 3.99K 4.1K 4.13K 4.12K 4.04K 6.03K